Integra LifeSciences Holdings C (IART) Stock Analysis

Integra LifeSciences splits its business into two segments: Codman Specialty Surgical, roughly 70% of total revenue, covering neurosurgery, neurocritical care, and ENT instrumentation, and Tissue Technologies, about 30%, focused on wound reconstruction, regenerative scaffolds, and private-label manufacturing. The company operates manufacturing and research sites across California, Massachusetts, New Jersey, Puerto Rico, France, Germany, Ireland, Israel, and Switzerland, and in 2025 no single customer accounted for more than 10% of consolidated revenue.

Integra sells its neurosurgical devices, surgical instruments, and regenerative tissue products through a combination of direct sales representatives organized by physician specialty and independent distributors serving hospitals, integrated health networks, group purchasing organizations, and surgery centers globally. Demand ties to hospital capital budgets and elective-procedure volume, with fourth-quarter revenue typically the strongest as hospitals spend down annual budgets. Raw materials such as bovine collagen, porcine urinary bladder matrix, and Manuka honey feed the Tissue Technologies platform, while certain components and raw materials are available only from one or a limited number of suppliers, a risk the company manages through long-term supply contracts and buffer inventory. On the pipeline side, Integra is pursuing FDA premarket approval for SurgiMend in post-mastectomy breast reconstruction and for DuraSorb in implant-based breast reconstruction, both targeted for 2026, following a 510(k) clearance for the Aurora Surgiscope cranial retractor system earlier in 2025. Competitors include divisions of Medtronic, Stryker, and Smith & Nephew.